Clinical Trial Update: Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of benralizumab for non-cystic fibrosis bronchiectasis was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-cystic Fibrosis Bronchiectasis

Drugs mentioned

• Benralizumab (Fasenra) (benralizumab)

Snippet

Sponsor: AstraZeneca | Conditions: Non-cystic Fibrosis Bronchiectasis | Phase 3 | Status: TERMINATED | Results posted: 2025-07-20